Managing toxicities associated with immune checkpoint inhibitors

被引：5

作者：

Park, Jiyeon Joy ^{[1
]}

Arafath, Syed ^{[2
]}

Kumar, Samir T. ^{[3
]}

Sharma, Roopali ^{[4
]}

Dixit, Deepali ^{[5
]}

机构：

[1] Rutgers State Univ, Ernest Mario Sch Pharm, Rutherford, NJ 08854 USA

[2] Presbyterian Weill Cornell Med Ctr Jama, Oncol Clin Pharm Specialist New York, Jamaica, NY USA

[3] SUNY Downstate Med Ctr, Internal Med Resident, Brooklyn, NY USA

[4] Touro Coll, Sch Pharm, Infect Dis Specialist, New York, NY USA

[5] Robert Wood Johnson Univ Hosp Piscataway, Rutgers & Clin Pharm Specialist Crit Care, Ernest Mario Sch Pharm, Piscataway, NJ USA

来源：

JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2021年 / 34卷 / 06期

关键词：

immune checkpoint inhibitor; toxicity; cancer; immune-related adverse events; adverse reaction; overactivation; DERMATOLOGICAL ADVERSE EVENTS; CANCER-PATIENTS; IPILIMUMAB; MANAGEMENT; NIVOLUMAB; METAANALYSIS; PNEUMONITIS; ANTI-PD-1; BLOCKADE;

D O I：

10.1097/01.JAA.0000735760.65235.3c

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent development of immunotherapy has led to remarkable advancement in cancer therapy. Drugs that inhibit the cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death-1 (PD-1) immune checkpoint pathways have shown improved patient survival. However, by altering the immune response to fight cancer, a new class of adverse reactions has emerged, known as immune-related adverse events. These adverse events are due to overactivation of the immune system in almost any organ of the body, can occur at any point in a patient's treatment course, and may become life-threatening. This article describes how to promptly recognize and manage these toxicities.

引用

页码：32 / 39

页数：8

共 50 条

[41] Cardiotoxicities associated with immune checkpoint inhibitors
Yang, Shu
Asnani, Aarti
CURRENT PROBLEMS IN CANCER, 2018, 42 (04) : 422 - 432
[42] Cutaneous toxicities of immune checkpoint inhibitors in patients with altered immunity
Thompson, Leah L.
Blum, Amy E.
Reardon, Rachel
Polyakov, Nicole J.
Krasnow, Nira A.
Yoon, Jaewon
Chang, Michael S.
Chen, Steven T.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (01) : 172 - 174
[43] Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
Xu, Ya
Fu, Yang
Zhu, Bo
Wang, Jun
Zhang, Bicheng
FRONTIERS IN IMMUNOLOGY, 2020, 11
[44] Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors
Mok, Kevin
Wu, Claudia
Chan, Stephen
Wong, Grace
Wong, Vincent Wai-Sun
Ma, Brigette
Lui, Rashid
CLINICAL COLORECTAL CANCER, 2024, 23 (01) : 4 - 13
[45] Dermatologic Reactions to Immune Checkpoint Inhibitors Skin Toxicities and Immunotherapy
Sibaud, Vincent
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (03) : 345 - 361
[46] Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis
Shieh, Christine
Chalikonda, Divya
Block, Peter
Shinn, Brianna
Kistler, C. Andrew
ANNALS OF GASTROENTEROLOGY, 2021, 34 (01): : 46 - 52
[47] Cardiotoxicity Associated with Immune Checkpoint Inhibitors
Minegishi, Shintaro
Horita, Nobuyuki
Ishigami, Tomoaki
Hibi, Kiyoshi
CANCERS, 2023, 15 (22)
[48] Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities
Roberts, Kate
Culleton, Vanessa
Lwin, Zarnie
O'Byrne, Kenneth
Hughes, Brett G. M.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (04) : 277 - 288
[49] Rechallenge with immune checkpoint inhibitors beyond severe toxicities, an utopia?
Medina Rodriguez, Laura
Jimenez-Rodriguez, Begona
Llacer, Casilda
Trigo Perez, Jose Manuel Manuel
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
Widmann G.
Nguyen V.A.
Plaickner J.
Jaschke W.
Current Radiology Reports, 5 (11)

← 1 2 3 4 5 →